Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

NCT05926700 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Candonilimab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University